MLSS vs. LUCD, SPAI, INO, HYPR, PDEX, OBIO, APYX, NSPR, FONR, and NTRB
Should you be buying Milestone Scientific stock or one of its competitors? The main competitors of Milestone Scientific include Lucid Diagnostics (LUCD), Safe Pro Group (SPAI), Inovio Pharmaceuticals (INO), Hyperfine (HYPR), Pro-Dex (PDEX), Orchestra BioMed (OBIO), Apyx Medical (APYX), InspireMD (NSPR), Fonar (FONR), and Nutriband (NTRB). These companies are all part of the "medical equipment" industry.
Milestone Scientific vs. Its Competitors
Milestone Scientific (NYSE:MLSS) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.
Milestone Scientific has higher revenue and earnings than Lucid Diagnostics. Milestone Scientific is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Milestone Scientific has a net margin of -52.01% compared to Lucid Diagnostics' net margin of -1,476.35%. Lucid Diagnostics' return on equity of 0.00% beat Milestone Scientific's return on equity.
5.8% of Milestone Scientific shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 24.8% of Milestone Scientific shares are held by company insiders. Comparatively, 6.8% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Milestone Scientific presently has a consensus price target of $1.25, indicating a potential upside of 180.77%. Lucid Diagnostics has a consensus price target of $3.70, indicating a potential upside of 200.81%. Given Lucid Diagnostics' higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Milestone Scientific.
In the previous week, Milestone Scientific had 4 more articles in the media than Lucid Diagnostics. MarketBeat recorded 9 mentions for Milestone Scientific and 5 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.59 beat Milestone Scientific's score of -0.03 indicating that Lucid Diagnostics is being referred to more favorably in the news media.
Milestone Scientific has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Summary
Milestone Scientific and Lucid Diagnostics tied by winning 8 of the 16 factors compared between the two stocks.
Get Milestone Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MLSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Milestone Scientific Competitors List
Related Companies and Tools
This page (NYSE:MLSS) was last updated on 10/16/2025 by MarketBeat.com Staff
